Abstract
Background & Objectives:The hallmark of rheumatoid arthritis is the inflammation that is mediated by the macrophages and monocytes that cause release of pro-inflammatory cytokines like interleukin-18. It is highly expressed in serum of patients suffering from rheumatoid arthritis and has a positive association with disease activity. The aim of this study was to analyze the gene expression of interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy.Methods:The cross sectional comparative study is conducted at Department of Biochemistry and Molecular Biology and Center for Research in Experimental and Applied Medicine (CREAM-1Lab), Army Medical College, Rawalpindi, in collaboration with Rheumatology Department, Military Hospital, Rawalpindi. Study was conducted on two groups consisting of Group-I of rheumatoid arthritis patients on diseases modifying anti-rheumatic drugs and control Group-II comprising of normal healthy individuals. Non-probability purposive sampling was done from patients and controls. The duration of study was one year i-e from November 2015 to November 2016. Relative quantification of gene expression of interleukin-18 was done by Real time PCR using ∆∆CT method.Results:Expression analysis for interleukin-18 showed down regulation of gene in rheumatoid arthritis patients as compared to controls.Conclusion:Interleukin-18 gene shows down regulation in rheumatoid arthritis patients on disease modifying anti-rheumatic drugs therapy.
Highlights
Rheumatoid Arthritis (RA) is a prevailing and debilitating autoimmune disease; characterized by chronic inflammation and joint destruction.[1]
This criterion is based upon four variables i-e small joint involvement, at least 6 months disease duration, positive serology for rheumatoid factor (RF) or anticyclic citrullinated peptide and presence
The aim of our study was to evaluate the expression of IL-18 in RA patients on Disease Modifying Anti-Rheumatic Drugs (DMARD) therapy compared to expression in healthy controls, in context with local population
Summary
Rheumatoid Arthritis (RA) is a prevailing and debilitating autoimmune disease; characterized by chronic inflammation and joint destruction.[1] It is a systemic disease that causes both cartilage and joint destruction leading to loss of function It is mostly present at an age of 4550 years and above, with higher prevalence in females than in males.[2]. The hallmark of rheumatoid arthritis is the inflammation that is mediated by the macrophages and monocytes that cause release of pro-inflammatory cytokines like interleukin-18 It is highly expressed in serum of patients suffering from rheumatoid arthritis and has a positive association with disease activity. The aim of this study was to analyze the gene expression of interleukin-18 in rheumatoid arthritis patients on disease modifying anti-rheumatic drug therapy. Conclusion: Interleukin-18 gene shows down regulation in rheumatoid arthritis patients on disease modifying anti-rheumatic drugs therapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
